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Abstract
Pulmonary lymphangioleiomyomatosis (LAM) is a rare lung disease caused by mutations in
the tumor suppressor genes encoding Tuberous Sclerosis Complex (TSC) 1 and TSC2.
The protein product of the TSC2 gene is a well-known suppressor of the mTOR pathway.
Emerging evidence suggests that the pituitary hormone prolactin (Prl) has both endocrine
and paracrine modes of action. Here, we have investigated components of the Prl system in
models for LAM. In a TSC2 (+/-) mouse sarcoma cell line, down-regulation of TSC2 using
siRNA resulted in increased levels of the Prl receptor. In human LAM cells, the Prl receptor
is detectable by immunohistochemistry, and the expression of Prl in these cells stimulates
STAT3 and Erk phosphorylation, as well as proliferation. A high affinity Prl receptor antago-
nist consisting of Prl with four amino acid substitutions reduced phosphorylation of STAT3
and Erk. Antagonist treatment further reduced the proliferative and invasive properties of
LAM cells. In histological sections from LAM patients, Prl receptor immuno reactivity was
observed. We conclude that the Prl receptor is expressed in LAM, and that loss of TSC2
increases Prl receptor levels. It is proposed that Prl exerts growth-stimulatory effects on
LAM cells, and that antagonizing the Prl receptor can block such effects.
Introduction
Lymphangioleiomyomatosis (LAM) is a rare, progressive multisystem disease affecting women
of child bearing age which is characterized by proliferation of abnormal smooth muscle (SM)-
like LAM cells [1]. LAM patients are usually fertile females and a common disease manifesta-
tion is the appearance of SM tumours, i.e. LAM lesions, in the lung parenchyma [2]. Loss of
function of the tuberous sclerosis complex 2 (TSC2) gene has been observed in LAM [3].
Recent research has shown that the TSC2 gene encodes a protein that suppresses the mTOR
pathway [4–8]. The mTOR pathway affects several key cellular functions including protein
synthesis. Endocrine components of LAM have been suspected because females are
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predominantly affected, and because the disease is aggravated during pregnancy–a condition
associated with elevation of lactogenic hormones like prolactin [9,10].
Prl exerts a variety of functions related to growth, differentiation and metabolism in differ-
ent target tissues [11]. The hormone is most well-known as a lactogenic factor secreted from
the pituitary gland, but it is also clear that some functions of Prl are mediated by localized,
non-pituitary Prl production [12]. Extra-pituitary actions of Prl seem particularly relevant in
humans because of the presence of a separate promoter within the Prl gene [12,13]. Prl signals
via the Prl receptor (PrlR), a member of the cytokine receptor family. The PrlR is structurally
related to the GH receptor (GHR), and hormone binding leads to receptor dimerization and
activation of the JAK2-STAT-SOCS pathway [14]. Prl seems to only bind to the PrlR, whereas
GH can bind to both GHR and the PrlR.
GH and Prl stimulate cell proliferation and growth. Besides activating the STAT system,
these hormones stimulate protein synthesis, an effect for which the kinase AKT-mTOR-S6
plays an important role [15,16]. One prerequisite for cells to respond to GH/Prl is the level of
expression of the GH/Prl receptors, and suppressor of cytokine signalling 2 (SOCS2) is an
important regulator of GHR expression levels [17]. Knock-down of SOCS2 in cells and animals
increases the levels of GHR expression, leading to increased GH sensitivity [18,19].
Since LAM is related to increased activation of the mTOR system, attention has been
focussed on treatment with rapamycin analogues, and promising effects on the disease progres-
sion have been reported [20–22]. In this study, we have analysed the relationship between
TSC2 and the Prl system both in cell systems in which TSC2 expression levels have been altered
by siRNA transfection, and also in cell lines derived from LAM patients.
Materials and Methods
Cell culture, cell lysis and protein quantification
The cell line CRL-2620, obtained from American Type Culture Collection (ATCC) and origi-
nating from a TSC2 -/+ mouse sarcoma, was cultivated in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U/ml penicillin and
100 μg/ml streptomycin, at 37°C in an atmosphere of 5% CO2.
Human cells were isolated from patients with LAM/TSC who had given written informed
consent according to the Declaration of Helsinki. The study was approved by the Institutional
Review Board of Milan’s San Paolo Hospital. LAM/TSC cells were previously characterized as
a homogenous population of α-smooth muscle-like (ASM) cells. These cells have a mutation in
one TSC2 allele, and loss of function of the other TSC2 allele is suggested by the absence of any
TSC2 product [23]. The cells were grown in a 50:50 mixture of DMEM/Ham’s F12 (Gibco)
supplemented with hydrocortisone (2.5 ug/ml), EGF (10 ng/ml), sodium selenite (8.6 ng/ml),
insulin (25 ug/ml), transferrin 10 ug/ml), ferrous sulphate (0.445 ug/ml) and 15% FBS. Cells
were used between passages 5 and 15.
Cells were lysed in 50 mM Tris HCl, pH 7.5/150 mMNaCl/5 mM EDTA/0.5% Igepal NP-
40/1 mM Na3VO4/20 mMNaF/1 mM DTT/1 mM PMSF/1× protease inhibitor cocktail (Com-
plete mini, Roche). Cell debris was removed by centrifugation at 14,000× g for 15 minutes at
4°C. The concentration of Prl hormone for treatment was 200ng/ml, unless otherwise specified.
The protein content of the supernatant was determined using the bradford dye-binding
method [24].
Cell transfection, siRNA treatment of cells and quantitative PCR
Cell transfections using siRNAs directed against TSC2 and control siRNA were purchased
from QIAGEN. Electroporation, using AMAXA nucleofector technology (Lonza, Cologne,
Prolactin and LAM
PLOSONE | DOI:10.1371/journal.pone.0146653 January 14, 2016 2 / 13
Germany) was carried out using TSC2 siRNA with the sequence TTGCTGGAAGTTGATGCG
TAA, and a scrambled siRNA sequence was used as a control. Transfections were carried out
using 20nmol siRNA on 1.5 million cells with an Amaxa instrument (setting E14). Quantitative
RT-PCR was used to measure changes in TSC2 mRNA levels.
Western blot
Whole cell lysates were separated in SDS/PAGE gels and transferred to polyvinylidenediflour-
ide (PVDF) membranes (Millipore). After blotting, membranes were blocked in 5% non-fat
skimmed milk or BSA (Sigma–Aldrich, St. Louis, Missouri, USA) in Tris-Buffered Saline (TBS)
containing 0.1% Tween 20. Membranes were incubated with one or more of the following anti-
bodies, as specified in the figures: mouse anti-GHR B10 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), rabbit anti-PrlR M-170 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Human samples were probed with PrlR antibody clone 1A2B1 (Invitrogen, Carlsbad, CA,
USA). Antibodies to detect phosphorylated and un-phosphorylated STAT5, STAT3 and Erk
were obtained from Cell Signaling (Danvers, Massachusetts, USA). As a loading control,
GAPDH horseradish peroxidase conjugated antibody (Cell Signaling, Danvers, Massachusetts,
USA) was used. Primary specific HRP-conjugated secondary antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Membranes were visualized with an ECL
Western blotting detection system (Pierce, ThermoFisher Scientific Inc, Rockford, IL, USA)
according to the manufacturer's instruction, or using an Amersham ECL Prime Western Blot-
ting Detection Reagent from GE healthcare. Band intensities were assessed by densitometry,
and phospho-protein levels were normalized to the total levels of each respective protein.
Immunofluorescence staining and confocal laser scanning
For immunofluorescence staining, cells were grown on coverslips and cultured in the supple-
mented media at 37°C in an atmosphere of 5% CO2. Cells were fixed with ice-cold methanol
for 10 min, after which excess methanol was removed. After three subsequent washes with
PBS, cells were blocked and permeabilized for 1 hour with PBS containing 1% BSA, 5% goat
serum and 0.05% Triton X-100 (Sigma–Aldrich, St. Louis, Missouri, USA). The cell coverslips
were incubated with primary antibody (mouse anti-GHR B10 (Santa Cruz, CA, USA), mouse
anti-PrlR, clone 1A2B1 (Invitrogen, Carlsbad, CA, USA) and rabbit anti-PrlR M-170 (Santa
Cruz, CA, USA) overnight at 4°C, washed again 3 times with PBS, and incubated for 1 h at
room temperature in the dark with the secondary antibodies alexa fluor 488 goat anti-mouse
and alexa flour 594 goat anti-rabbit (both from Invitrogen, Carlsbad, CA, USA). Finally, the
slides were washed, mounted with Vectashield containing DAPI (H-1200, Vector Laboratories,
CA, USA) and stored at 4°C in the dark. Controls for specificity and background staining were
performed by incubating with mouse IgG or rabbit IgG antibodies. Image acquisition was per-
formed by confocal laser scanning microscopy (CLSM).
Immunohistochemistry analyses
Lung tissue samples were taken from patients with a diagnosis of LAM as confirmed by pulmo-
nary histopathology using both hematoxylin-eosin (H&E) staining, and also specific studies
(e.g., reactivity with monoclonal antibody HMB45). Tissue was obtained at lung transplanta-
tion or following lung biopsy for medically indicated reasons. Tissues from patients were used
after informed consent according to the Declaration of Helsinki.
Immunohistochemistry was carried out on de-paraffinized rehydrated 4 μm tissue sections.
For antigen retrieval, the slides were treated under pressure at 95°C in citrate buffer, pH 6.0
(Dako, Glostrup, Denmark) for 5 minutes. After cooling to room temperature, the sections
Prolactin and LAM
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were incubated with 0.3% H2O2 in methanol for 20 minutes to quench endogenous peroxidase
activity, and then incubated in TBS with 3% bovine serum at room temperature for 2 hours to
block non-specific binding. Sections were incubated at 4°C overnight with a primary antibody
against PrlR (1:100; Invitrogen, Carlsbad, CA, U.S.A.) diluted in 1.5% BSA. The sections were
then incubated with biotinylated secondary antibody (1:100; Vector Laboratories) for 2 hours
at room temperature, followed by incubation with Avidin-Biotin-Peroxidase Complex (Pierce,
Rockford, IL, USA). Detection was performed with peroxidase substrate DAB (3.3-diamino-
benzidine) (DAB substrate kit, Pierce). Haematoxylin was used as a counterstain. For negative
controls, the primary antibody was omitted. Negative controls were run in parallel in all experi-
ments. Images were captured by bright field microscopy under identical conditions of magnifi-
cation and illumination.
Cell proliferation assay
Cells were seeded in 96-well culture plates at a density of 1000 cells per 200μL culture medium
per well, and allowed to attach for 24–48 hours. The media was then removed and replaced
with serum-free medium, or medium containing 2% or 10% serum and 200ng/ml recombinant
human Prl (a generous gift from Novo Nordisk A/S, Denmark), with or without PrlR antago-
nist (PrlRA) as specified in the Figure legend. Relative cell numbers were assessed after 72
hours, using the colorimetric crystal violet assay. The cells were fixed within the wells by addi-
tion of 100μL 4% paraformaldehyde solution to 100μL medium. After 20 minutes, the formal-
dehyde was discarded, and the plates were washed with deionized water, air-dried, and stained
with 100μl crystal violet solution (0.04% (w/v) crystal violet in 1% ethanol) for 20 minutes at
room temperature. Excess dye was washed away with deionized water and the plates were air-
dried. Bound dye was then dissolved with 1% (w/v) SDS, and the optical densities of the
extracts were measured at 600 nm. Growth curves were created on the basis of the obtained
absorbance values.
Invasion assay
Human cells, isolated from a patient with LAM/TSC, were starved overnight. The invasive
properties of cells were analyzed using the CytoSelect™ Cell Invasion Assay kit (Cell Biolabs,
San Diego, CA), according to the manufacturer’s instructions. The assay kit includes polycar-
bonate membrane inserts, which serve as a barrier to discriminate invasive from non-invasive
cells. This analysis measures the invasive properties of cells, and depends on the degradation of
matrix proteins covering a polycarbonate membrane and cellular passage through the mem-
brane pores. The invading cells at the bottom of the polycarbonate membrane were stained
with a cell stain solution (supplied with the kit), and the cells were extracted using an extraction
solution. The optical densities of the extracts were measured at 560 nm. Growth charts were
created on the basis of the obtained absorbance values.
Prl receptor antagonist (PrlRA)
As previously shown, an amino acid substitution at position 129 in human Prl of a Gly for an
Arg generates a protein (hPrl-G129R) that blocks the Prl receptor [24,25]. Studies have shown
that Prl G129R competes with exogenous Prl when added in>10-fold molar excess to compen-
sate for its lower affinity for the PrlR [26,27]. In the present study, we used PrlRA, a protein
with increased receptor affinity due to the substitutions S33A, Q73L, G129R and K190R, to
block the receptor [28]. This protein was expressed and purified from E.coli cultures.
Prolactin and LAM
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Statistical analysis
Routinely, treatments were performed in triplicates, and experiments were repeated at least
three times on several occasions. Statistical significance of the differences was evaluated using
unpaired, 2-tailed Student’st-test, and was considered significant when the significance level of
the test was p< 0.05.
Results
Increased expression of PrlR after treatment of CRL-2620 mouse cell
line with TSC2 siRNA
CRL-2620 was originally obtained from a cutaneous sarcoma taken from a TSC2 +/- mouse.
Since this cell line is TSC2 (+/-), siRNA was used to knock down remaining TSC2 expression.
Quantitative RT-PCR was used to test the efficacy of two different TSC2 siRNAs. Both siRNAs
down-regulated TSC2 mRNA levels, with the most pronounced effect (approximately 60%
down-regulation) being seen with TSC2 siRNA_3. This was used in further experiments (Fig
1A).
The Western blot technique was used to monitor protein expression following TSC2 siRNA
treatments. The levels of PrlR expression were increased in cells treated with TSC2 siRNA (Fig
1B). On the other hand, TSC2 siRNA treatment did not change the levels of GHR. The changes
in protein levels were quantified by densitometry, and TSC2 siRNA treatment increased Prl
receptor expression by a factor of six-fold (Fig 1C).
The above findings were confirmed by immunohistochemical staining studies of cells
treated with TSC2 siRNA, compared with control siRNA. Images were acquired by confocal
laser microscopy, as shown in (Fig 2). PrlR immunostaining was markedly increased following
TSC2 knockdown. A strong immunofluorescence signal was observed at intracellular locations,
including the nucleus. GHR immune reactive\ity was also assessed in the same specimen, and
is shown in (Fig 2). These experiments confirmed that PrlR staining was increased in the pres-
ence of reduced TSC2 levels, while GHR staining was not altered.
Detection of PrlR in human LAM/TSC cells and in human LAM tissue
Human LAM/TSC cells were used for further experiments. Analyses of PrlR expression in
these cells were carried out by immunohistochemistry using two different anti-PrlR antibodies,
and, as shown in (Fig 3), both antibodies gave a clear staining pattern.
PrlR was highly expressed in the lungs of patients affected by LAM, and positivity for PrlR
antibody staining was higher in LAM tissue, compared to normal lung tissue. The localization
of the labeling was diffuse, and the immuno reactivity of cells within LAM lesions was variable,
being localized either within nuclei or in the cytoplasm (Fig 4). Further analyses of PrlR in
LAM/TSC cells using antibodies against human PrlR detected a protein band of 89–90 kD (Fig
5A).
Prl phosphorylates STAT3/Erk, but not STAT5, in human LAM/TSC cells
The short-term effects of Prl on the phosphorylation of intracellular protein targets were tested
in cells exposed to Prl. We were unable to detect any change in STAT5 phosphorylation in
these cells (data not shown), whereas STAT3 and Erk were phosphorylated by Prl (Fig 5B). To
block the effect of prolactin, LAM/TSC cells were starved overnight, and then incubated for 15
minutes with PrlRA (20, 50, 200 ng/ml). Prl (200 ng/ml) was subsequently added to the
medium for 1 hour, after which phosphorylation of STAT3 and Erk was analysed by Western
blotting (Fig 5B). In tests of the different doses of PrlRA, we found that 200 ng/ml of PrlRA
Prolactin and LAM
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decreased Prl-induced phosphorylation of STAT3 and Erk. (Fig 5B) further shows that PrlRA
reduced phosphorylation of STAT3/Erk even in the absence of Prl.
PrlR signalling stimulates LAM/TSC cell growth in a manner which can
be blocked by a PrlRA
To evaluate whether LAM/TSC cells react to Prl stimulation, cells were cultured at different
serum concentrations. Addition of human Prl resulted in growth stimulation, as assessed using
the crystal violet method. A response to Prl was seen at all of the serum concentrations tested,
Fig 1. Effect of TSC2 siRNA on GHR and PrlR expression. The mouse cell line CRL-2620 was transfected with two different TSC2 siRNAs (siRNA_1 and
siRNA_3), or a control siRNA (si_C). (A) Quantitative RT-PCR was used to test the efficacy with which these siRNAs down-regulated TSC2mRNA. The most
pronounced effect (approximately 60% reduction) was seen with TSC2 siRNA_3, which was used for further experiments. (B) The figure shows a
representative Western blot probed with antibodies directed to GHR, PrlR, SOCS3 and GAPDH; iGHR and mGHR, are the immature and mature forms of
GHR, respectively. (C) Densitometric analyses of Western blots. Protein lysates were prepared individually from three separate culture dishes treated with
TSC2 siRNA or control siRNA and subject to Western blot analysis; experiments were repeated three times and gave consistent results. * = P-value <0.05.
doi:10.1371/journal.pone.0146653.g001
Prolactin and LAM
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Fig 2. Immunofluorescence of CRL-2620 using PrlR and GHR antibodies. Cells were transfected with TSC2 or control siRNAs. After over-night
incubation, the cells were washed 3 times with PBS and incubated with antibodies for PrlR and GHR. The figures show that PrlR immunostaining was
markedly increased following TSC2 knock-down. A strong immunofluorescence signal was observed at intracellular locations. In the negative control panel,
cells were incubated with mouse IgG and rabbit IgG antibodies. Fluorescence images were acquired at a magnification of 63x.
doi:10.1371/journal.pone.0146653.g002
Fig 3. Detection of PrlR in human LAM cells using immunofluorescence. Staining LAM/TSC cells using different PrlR antibodies detect a significant
immunofluorescence signal in LAM/TSC cells. The antibodies employed were U5 (Thermoscientific) and A12B1 (Invitrogen).
doi:10.1371/journal.pone.0146653.g003
Prolactin and LAM
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and tended to be largest in high (10%) serum concentrations (Fig 6). Addition of PrlRA (20,
50, 200 ng/ml) significantly inhibited Prl-induced LAM cell growth in a dose-dependent man-
ner (Fig 6).
We studied the invasive properties of human LAM/TSC tumor cells exposed to Prl and the
PrlRA. At the conditions used, Prl did not significantly stimulate cell invasion, but the combi-
nation of Prl and PrlRA decreased the extent of invasion by approximately 60% (Fig 7).
Discussion
In this study, we show that PrlR levels are increased in a mouse sarcoma cell line treated with
TSC2 siRNA. Interestingly, the GH receptor was only marginally affected by TSC2 knock-
down, suggesting that changes in PrlR levels due to reductions in TSC2 expression had rela-
tively specific effects in the cell system used. We also found that the Prl receptor is readily
detectable in cells derived from human LAM lesions. These cells respond to Prl by increasing
proliferation and by phosphorylation of STAT3 and Erk. The invasive capacity of human LAM
cells can be reduced by use of PrlRA. Analyses of patient material from LAM patients showed
that LAM lesions express PrlR. Taken together; our results support the idea that LAM cells are
Prl-dependent.
A mechanistic explanation for increased Prl sensitivity in LAM cells requires further studies,
but it is interesting that elimination of one signalling component (i.e. TSC2) can influence the
composition of membrane proteins. For example, previous work has demonstrated that expres-
sion of integrin can be altered by changes in TSC2 [29]. TSC2 is a GTPase-activating protein
which, via the targeting of RHEB, suppresses the activity of mTORC1 [8]. Consequently, elimi-
nation of TSC2 activates mTORC1 and its downstream effector signals, including S6 kinase,
leading to diverse cellular responses that include increased protein synthesis. One regulator of
TSC2 is AKT, and stimulation of this kinase by e.g. growth-promoting agents, destabilizes
TSC2, resulting in increased mTORC1 activity [30]. Another system that regulates mTORC1 is
the “energy sensor” AMP kinase that senses changes in the cellular ATP/AMP ratio [31]. Prl is
known to activate AKT, and as a growth-stimulating factor, it also changes AMP kinase activ-
ity. The most well studied effects of PrlR signalling involve the JAK2 and STAT (notably
STAT5) pathway, and JAK2 activation is in turn dependent upon PrlR dimerization due to Prl
Fig 4. Prolactin receptor immuno reactivity in human LAM lung lesions.Histological sections from LAM patients were analyzed. Human lung tissues
were obtained from subjects who underwent lung resection for diagnostic reasons and immunohistochemical-staining using the PrlR antibody clone 1A2B1
(Invitrogen) was carried out. Arrows indicate the location of PrlR immuno reactivity in one microscope field of a representative image from LAM tissue;
compared to positive cells for PrlR in control lung tissue. For negative control, primary antibody was omitted, Scale bars: 50 μm.
doi:10.1371/journal.pone.0146653.g004
Prolactin and LAM
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binding to two PrlRs. The regulation of STAT3 by Prl observed in this study confirms previous
studies, and activation of this transcription factor seems to be of particular relevance for LAM
cell growth; indeed, a study by Goncharova et al. [32] showed that phosphorylation of STAT3
is critical for the enhanced growth of LAM cells.
Fig 5. Human LAM cells express PrlR, and prolactin stimulates phosphorylation of STAT3 and Erk. LAM/TSC cells were cultured in serum-free
medium overnight. The cells were then exposed to different doses of PrlRA (20, 50, 200 ng/ml) for 15 minutes, and subsequently the cells were exposed to
200 ng/ml Prl for 60 minutes or PBS as a control. Then protein extracts were prepared for Western blot analysis, and probed with antibodies for P-STAT3,
STAT3, P-Erk and Erk. (A) Western blot to analyze PrlR in LAM/TSC control cells; an antibody against human PrlR detected a protein band of 89–90 kD. (B)
Western blot, using antibodies directed against P-STAT3, STAT3, P-Erk and Erk in LAM/TSC cells following treatment as described in Material and methods
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As previously described [32], increased STAT3 phosphorylation is also seen in TSC2-null
xenografted tumors. In some cell systems, SOCS3 is an established negative regulator of STAT
proteins, and elevation of SOCS3 can down-regulate membrane PrlRs [33]. In our experiments,
however, we found that SOCS3 was not changed by suppression of TSC2 levels, and therefore
other explanations which link reductions in TCS2 to increased Prl receptor expression are
needed.
Although our experiments only concerned experimental cell models, it is interesting to
speculate whether increased Prl sensitivity is of relevance for the growth of LAM lesions. A pre-
vious study by Terasaki et al. showed that LAM lesions produce Prl, and that patients with
LAM have elevated serum Prl levels [34]. Extra-pituitary Prl production in humans, due to the
presence of a separate gene promoter, has been elegantly shown by Horseman et al. by replac-
ing the mouse Prl promoter with its human counterpart [35,36].Taken together, there is room
to hypothesize that LAM lesions are hypersensitive to endocrine or locally produced Prl, and
that LAM lesions will respond to agents disrupting Prl signals. One way to block Prl signalling
is to block the Prl receptor. Prl receptor antagonists have been created by the introduction of
Fig 6. Addition of exogenous Prl stimulates cell proliferation in a manner which can be blocked by PrlRA. LAM/TSC cells were cultured in different
concentrations of serum (0%, 2%, 10%). Human Prl was added to sub-confluent cells at a concentration of 200 ng/ml, with or without PrlRA (20, 50, 200 ng/
ml). After 72 hours, cells were subject to the crystal violet assay. The X-axis depicts serum concentration and the Y-axis shows relative cell proliferation, as
determined by absorbance at 600 nm. Each data point represents a triplicate assay. All values are +/- standard deviation, P-value <0.05.
doi:10.1371/journal.pone.0146653.g006
Prolactin and LAM
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specific amino acid changes into Prl, which prevent receptor dimerization and activation. The
antagonist used in the present study is known to block Prl-induced STAT5 activation, and we
observed that blocking PrlR reduced Prl-induced activation of STAT3 and Erk in LAM cells. In
the present study, we observed that the PrlR antagonist could exert its action alone, i.e. in the
absence of Prl. We do not have a clear explanation for this effect, but further studies concerning
e.g. the local production of Prl might provide an explanation for this phenomenon. Future
studies are needed to clarify the potential role of PrlR antagonists in the treatment of LAM.
In conclusion, reductions in levels of TSC2 in cells leads to increases in PrlR levels, and
antagonism of this receptor may offer a new therapeutic approach in the treatment of LAM.
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